Recent Updates
Recently added Catalysts
ONCY

CERTIFICATION ex99.htm FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: 1. Review: I have reviewed the interim financi

Thursday, May 13, 2010 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CERTIFICATION OF INTERIM FILINGS I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: WSLegal\052277\00014\5218666v1 CERTIFICATION OF INTERIM FILINGS I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the following: WSLegal\052277\00014\5

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
7%
average across 3 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
REOLYSIN
Phase 3 · Carcinoma, Squamous Cell of the Head and Neck

Full Press Release Details

CERTIFICATION OF INTERIM FILINGS
I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following:
WSLegal\052277\00014\5218666v1
CERTIFICATION OF INTERIM FILINGS
I, Doug Ball, CFO of Oncolytics Biotech Inc., certify the following:
WSLegal\052277\00014\5218666v1
ShareAdd on Google
Tags: ONCY Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: May 13, 2010

Biotech snapshot

Cash runway
$4M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
REOLYSINPhase 3
Carcinoma, Squamous Cell of the Head and Neck →

Catalyst track record

+48%
best trade around ONCY's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for ONCY.

See every catalyst's timing & PoA →